APA (7th ed.) Citation

M, P., CM, G., R, C., T, H., & R, M. (2026). Impact of adjunct bezlotoxumab for preventing Clostridioides difficile infection recurrence in patients post - hematopoietic stem cell transplantation. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 32(4), 676. https://doi.org/10.1177/10781552241310099

Chicago Style (17th ed.) Citation

M, Patel, Gill CM, Chamberland R, Heflin T, and Mehringer R. "Impact of Adjunct Bezlotoxumab for Preventing Clostridioides Difficile Infection Recurrence in Patients Post - Hematopoietic Stem Cell Transplantation." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 32, no. 4 (2026): 676. https://doi.org/10.1177/10781552241310099.

MLA (9th ed.) Citation

M, Patel, et al. "Impact of Adjunct Bezlotoxumab for Preventing Clostridioides Difficile Infection Recurrence in Patients Post - Hematopoietic Stem Cell Transplantation." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, vol. 32, no. 4, 2026, p. 676, https://doi.org/10.1177/10781552241310099.